Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company announced three subscription agreements on August 14, 2025, with different investors, agreeing to issue a total of 136 million shares at a subscription price of 0.097 HKD per share [1] - The total amounts for the subscription agreements are 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively for the three agreements [1] Group 2 - The net proceeds from the subscription will be used for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [2] - The company aims to expand its health-related business opportunities into overseas markets while continuing to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The stock of Jingyou Pharmaceutical (00858) surged over 13%, reaching a price of 0.134 HKD with a trading volume of 2.323 million HKD [1] - The company entered into subscription agreements with three different parties on August 14, 2025, for a total of 300 million HKD in new shares at a price of 0.097 HKD per share [1][2] - The total amount from the subscription agreements is 2.91 million HKD, 1.94 million HKD, and 10.67 million HKD respectively, with conditions that must be met for the agreements to be finalized [1][2] Group 2 - The net proceeds from the subscription agreements will be used for the development of new business opportunities in health products, equipment, and technology trade in China, as well as expanding into overseas markets [2] - The company will continue to utilize its existing cash resources to maintain and develop its current pharmaceutical business [2]

Group 1 - The company has entered into subscription agreements with three subscribers to issue a total of 160 million shares at a subscription price of HKD 0.097 per share, raising a total of HKD 2.91 million, HKD 1.94 million, and HKD 10.67 million respectively [2] - The net proceeds from the subscription will be used to support the group's potential new business development in the trade, manufacturing, sales, and distribution of health products, equipment, and technology in China, as well as to expand into overseas health-related business opportunities [2] - The company plans to continue using internal cash resources to maintain and develop its existing pharmaceutical business, believing that factors such as an aging population, increasing chronic diseases, heightened health awareness, and technological advancements will sustain the demand for health and patient care products and solutions in the healthcare industry [2]

Group 1 - The core point of the news is that 精优药业 announced a new share issuance to raise approximately 15.52 million HKD for potential business development in health products and related opportunities [1][2] - The company issued a total of 160 million shares to three different subscribers, with the share price set at 0.097 HKD, representing a discount of about 17.8% from the closing price on August 14, 2025 [1] - The funds raised will be used for the development of health products, equipment, and technology trade, as well as sales and distribution in China and potential overseas markets [2] Group 2 - The issuance is based on a general authorization granted by the shareholders' meeting, and the completion of the subscriptions is subject to certain conditions [2] - The shares issued to each subscriber represent a small percentage of the existing and enlarged share capital, with Subscriber I accounting for approximately 1.26% of the existing capital and 1.24% of the enlarged capital [1] - The completion of the subscriptions is expected to occur within 7 business days after the conditions are met [2]

Group 1 - The company has entered into three subscription agreements with different subscribers, agreeing to issue a total of 1.43 billion shares at a subscription price of HKD 0.097 per share, raising a total of HKD 1.55 billion [1][2] - The first agreement involves the issuance of 30 million shares for a total of HKD 2.91 million, the second agreement involves 20 million shares for HKD 1.94 million, and the third agreement involves 110 million shares for HKD 10.67 million [1] - The subscription matters are conditional and will only be finalized upon the fulfillment of specified conditions [1] Group 2 - The net proceeds from the subscription will be used to develop potential new business in health products, equipment, and technology trade, manufacturing, sales, and distribution in China, as well as to expand related business opportunities overseas [2] - The company believes that the demand for products and solutions that improve health and patient care will continue to grow due to factors such as an aging population, increasing prevalence of chronic diseases, heightened health awareness, and technological advancements [2] - The net proceeds will support the company in seizing new business opportunities more effectively [2]

Core Viewpoint - The company, 精优药业, has entered into subscription agreements with three parties to issue new shares at a price of HKD 0.097 per share, which represents a discount to the market price on the date of the agreements [1][2][3] Group 1: Subscription Agreements - The company has signed Subscription Agreement I with subscriber I (曾广钊) to issue 30 million shares, representing approximately 1.26% of the existing issued share capital [1] - Subscription Agreement II was signed with subscriber II (张晓佳) for 20 million shares, equivalent to about 0.84% of the existing issued share capital [1] - Subscription Agreement III was established with subscriber III (Fudan Health International Ltd.) for 110 million shares, accounting for approximately 4.6% of the existing issued share capital [2] Group 2: Financial Implications - If all shares from Subscription Agreement I are successfully issued, the total proceeds will be approximately HKD 2.91 million, with a net amount of about HKD 2.89 million [3] - For Subscription Agreement II, the total proceeds are expected to be around HKD 1.94 million, with a net amount of approximately HKD 1.93 million [3] - The proceeds from Subscription Agreement III are projected to total about HKD 10.67 million, with a net amount of approximately HKD 10.60 million [3] Group 3: Use of Proceeds - The net proceeds from the subscriptions will be utilized for potential new business development in health products, equipment, and technology trade, manufacturing, sales, and distribution in China [3] - The company aims to expand its health-related business opportunities into overseas markets while continuing to maintain and develop its existing pharmaceutical business through internal cash resources [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 （ 於百慕達註冊成立之有限公司） （股份代號：00858） 根據一般授權發行新股份 認購協議I 於二零二五年八月十四日（ 交易時段後 ），本公司與認購方I訂立認購協議I，據此，認購 方I已有條件同意認購，而本公司已有條件同意按認購價（I 總金額為2,910,000港元，相等 於每股認購股份I 0.097港元）配發及發行合共30,000,000股認購股份I。根據認購協議I進行 之認購事項I須待條件I達成後方可作實。 根據認購事項 I將予配發及發 行之認購股份I 相當於(i)於 本公告日期本公司 現有已發行股 本約1.26%；及(ii)經配發及發行認購股份I擴大之本公司已發行股本約1.24%（ 假設本公司 已發行股本於本公告日期至完成I期間將不會有任何變動，且並無計及本公司根據認購事 項II可能配發及發行之認購股份II以及本公司根據認購事 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 精優藥業控股有限公司 (於百慕達註冊成立之有限公司) 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00858 | 說明 | 精優藥業 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.01 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.01 | H ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of Jingyou Pharmaceutical, which saw a 5.47% increase, reaching a price of 0.135 HKD per share with a trading volume of 2.3585 million HKD [1] - Jingyou Pharmaceutical Holdings Limited primarily focuses on promoting and selling pharmaceutical products in the Chinese market, researching gene-related technologies, and developing oral insulin products through joint ventures [1] - As of the 2024 annual report, Jingyou Pharmaceutical reported total revenue of 51.1515 million HKD and a net profit of 205 million HKD [2]

(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） （Stock Code 股份代號：858） NOTIFICATION LETTER 通知信函 Should you have any queries relating to any of the above matters, please call the Hong Hong Branch Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday (excluding public holidays). By order of the Board Extrawell Pharmaceutical Holdings Limited Xie Yi Chairman Notes: 各位非登記持有人 （附註1） ： Dear Non-Registered Holder (Note 1) , 29 July ...